Topiramate (Epilepsy)

ASD (Autism spectrum disorder): Risk

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9960
R35823		 Bjørk (Topiramate) (Controls exposed to Lamotrigine, sick), 2018 Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) during pregnancy (anytime or not specified) population based cohort propective exposed to other treatment, sick excluded Adjustment: No 0.97 [0.10;9.00] C
excluded (control group) 		1/6   13/76 14 6
ref
S9955
R35818		 Bjørk (Topiramate) (Controls unexposed, disease free), 2018 Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) during pregnancy (anytime or not specified) population based cohort propective unexposed, disease free excluded Adjustment: No 1.99 [0.23;17.00] C
excluded (control group) 		1/6   6,907/75,497 6,908 6
ref
S9957
R35820		 Bjørk (Topiramate) (Controls unexposed, sick), 2018 Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) during pregnancy (anytime or not specified) population based cohort propective unexposed, sick Adjustment: No 1.81 [0.20;16.11] C 1/6   27/272 28 6
ref
S6183
R16278		 Wood (Topiramate), 2015 Score 27-29 (CARS) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 17.00 [0.13;2166.90] C 0/1   0/9 0 1
ref
Total 2 studies 2.65 [0.36;19.38] 28 7
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bjørk (Topiramate) (Controls unexposed, sick), 2018Bjørk, 2018 1 1.81[0.20; 16.11]28683%ROB confusion: unclearROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Wood (Topiramate), 2015Wood, 2015 2 17.00[0.13; 2166.90]0117%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: criticalROB mesure: lowROB reporting: moderate Total (2 studies) I2 = 0% 2.65[0.36; 19.38]2870.550.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate) (Controls unexposed, sick; 2: Topiramate;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.65[0.36; 19.38]2870%NABjørk (Topiramate) (Controls unexposed, sick), 2018 Wood (Topiramate), 2015 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.81[0.20; 16.11]286 -NABjørk (Topiramate) (Controls unexposed, sick), 2018 1 exposed to other treatment, sickexposed to other treatment, sick 17.00[0.13; 2166.90]-1 -NAWood (Topiramate), 2015 1 Tags Adjustment   - No  - No 2.65[0.36; 19.38]2870%NABjørk (Topiramate) (Controls unexposed, sick), 2018 Wood (Topiramate), 2015 2 All studiesAll studies 2.65[0.36; 19.38]2870%NABjørk (Topiramate) (Controls unexposed, sick), 2018 Wood (Topiramate), 2015 20.550.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9960, 9955

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.99[0.23; 17.00]6,9086 -NABjørk (Topiramate) (Controls unexposed, disease free), 2018 1 unexposed, sick controlsunexposed, sick controls 1.81[0.20; 16.11]286 -NABjørk (Topiramate) (Controls unexposed, sick), 2018 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.75[0.18; 16.93]14710%NABjørk (Topiramate) (Controls exposed to Lamotrigine, sick), 2018 Wood (Topiramate), 2015 20.510.01.0